Patents by Inventor Run CHANG

Run CHANG has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220227810
    Abstract: Disclosed are peptides comprising an amphiphilic backbone and a cationic heparin-binding motif peptide. The peptides can be used in methods of antimicrobial treatment.
    Type: Application
    Filed: November 12, 2021
    Publication date: July 21, 2022
    Inventors: Run Chang, Keerthana Subramanian, Mian Wang, Thomas J. Webster
  • Patent number: 11174288
    Abstract: Disclosed are peptides comprising an amphiphilic backbone and a cationic heparin-binding motif peptide. The peptides can be used in methods of antimicrobial treatment.
    Type: Grant
    Filed: December 5, 2017
    Date of Patent: November 16, 2021
    Assignee: Northeastern University
    Inventors: Run Chang, Keerthana Subramanian, Mian Wang, Thomas J. Webster
  • Publication number: 20180179255
    Abstract: Disclosed are peptides comprising an amphiphilic backbone and a cationic heparin-binding motif peptide. The peptides can be used in methods of antimicrobial treatment.
    Type: Application
    Filed: December 5, 2017
    Publication date: June 28, 2018
    Inventors: Run Chang, Keerthana Subramanian, Mian Wang, Thomas J. Webster
  • Publication number: 20170202783
    Abstract: Nanoparticulate carrier formulations are useful to solubilize, deliver, and target hydrophobic drugs for treating diseases including cancer and bacterial infections. The formulations contain amphiphilic peptides having a hydrophobic portion and a positively charged hydrophilic portion. The peptides self-associate at nonacidic pH to form mi-celles with a spherical nanoparticle morphology. The hydrophobic core of the nano-particles encapsulates hydrophobic drugs, including antitumor agents, increasing their solubility in water and allowing them to be targeted, for example, to cancer cells. The positively charged surface of the nanoparticles, together with an optional targeting moiety such as an RGD peptide, allows the nanoparticles to bind selectively to mammalian cells and bacterial cells, including cancer cells that overexpress integrin receptors.
    Type: Application
    Filed: July 8, 2015
    Publication date: July 20, 2017
    Inventors: Run CHANG, Linlin SUN, Thomas Jay WEBSTER, Gujie MI